Landry Robert E 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Landry Robert E
SVP Fin, Dep CFO
Transactions
- Exercise/Conversion
Common Stock
2024-01-31$378.98/sh+400$151,592→ 23,856 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-01-31−400→ 12,187 totalExercise: $378.98Exp: 2027-12-12→ Common Stock (400 underlying) - Tax Payment
Common Stock
2024-01-31$953.42/sh−282$268,864→ 23,574 total
Holdings
- 270(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.